Russia's type 2 diabetes drug market will grow to $1.7 billion in 2015

Russia’s type 2 diabetes drug market will grow more than seven percent annually from $1.2 billion in 2010 to $1.7 billion in 2015. According to Decision Resources’ new Emerging Markets report, titled Type 2 Diabetes in Russia, growth will be driven by the introduction of several premium-priced agents and the increasing use of glucagon-like peptide 1 (GLP-1) analogues, dipeptidyl peptidase (DPP-IV) inhibitors and insulin analogue mixes.

There are a number of drugs in the type 2 diabetes pipeline, with 14 agents expected to launch in Russia by 2015, including two drugs in a novel class of sodium glucose cotransporter (SGLT)-2 inhibitors, Bristol-Myers Squibb/AstraZeneca’s dapagliflozin (which has not yet gained regulatory approval but received a negative recommendation from a US Food and Drug Administration advisory panel; The Pharma Letter July 20) and Johnson & Johnson’s canagliflozin, which the company expects to file for US and European approval in the first half of next year (TPL May 27).

Most insulins reimbursed